OXBDF (Oxford BioMedica) YoY EBITDA Growth: 53.23% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OXBDF Oxford BioMedica PLC OXBDF
72 GF Score
Price $7.34
GF Value $7.29
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica YoY EBITDA Growth?

Oxford BioMedica OXBDF 72 YoY EBITDA Growth is 53.23% as of Dec. 2025. GuruFocus rates OXBDF with a GF Score™ of 72/100 and a GF Value™ of $7.29 (Fairly Valued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Oxford BioMedica's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 53.23%.

Oxford BioMedica's EBITDA per Share for the six months ended in Dec. 2025 was $0.10.

Oxford BioMedica YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica YoY EBITDA Growth Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 655.71 -126.47 -1,291.43 91.02 116.57

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,029.73 44.15 104.06 67.52 53.23
OXBDF
72GF Score
Oxford BioMedica PLC OXBDF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Oxford BioMedica's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.029--0.175)/ | -0.175 |
=116.57 %

Oxford BioMedica's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(0.095-0.062)/ | 0.062 |
=53.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 53.23% mean?
Oxford BioMedica (OXBDF) has a YoY EBITDA Growth of 53.23% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Oxford BioMedica and its competitors.
Is Oxford BioMedica's YoY EBITDA Growth too high?
Oxford BioMedica's current YoY EBITDA Growth is 53.23%. Overall, Oxford BioMedica has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's YoY EBITDA Growth compare to VRTX and REGN?
Oxford BioMedica's YoY EBITDA Growth of 53.23% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Oxford BioMedica and its competitors. Oxford BioMedica's current YoY EBITDA Growth is 53.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Fairly Valued. The stock's GF Value™ is $7.29, compared to a current price of $7.34 — trading 0.7% above its estimated fair value. The current YoY EBITDA Growth is 53.23%. Oxford BioMedica's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current YoY EBITDA Growth is 53.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (OXBDF) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of $7.34 is trading 0.7% above its estimated GF Value™ of $7.29. GuruFocus considers Oxford BioMedica to be Fairly Valued.

Key valuation signals for OXBDF:

  • YoY EBITDA Growth: 53.23%
  • GF Value™: $7.29 vs. price of $7.34 (0.7% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBl:UKOXB:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
72GF Score

Get the complete analysis for OXBDF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.34
Price
$7.29
GF Value